Product Description
Esmolol (esmolol hydrochloride) is an intravenous cardioselective beta-1 adrenergic antagonist. Esmolol is used in various settings, including urgent care, perioperatively, and postoperatively. It is indicated in sinus tachycardia, where a rapid rate requires intervention secondary to other comorbidities. Esmolol is FDA-approved for tachycardia and hypertension induced by intubation. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK518965/)
Mechanisms of Action: ADRB Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Venezuela
Approved Indications: Atrial Fibrillation | Atrial Flutter | Heart Block | Tachycardia | Tachycardia, Sinus | Tachycardia, Supraventricular | Tachycardia, Ventricular | Ventricular Fibrillation | Ventricular Flutter | Hypertension
Known Adverse Events: Hypotension | Dizziness | Hyperhidrosis
Company: Novalead Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Spain
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CIBERbBECHO | P3 |
Recruiting |
Liver Cirrhosis |
2027-03-01 |